Tekirdağ Namık Kemal University

Running trials

• Recruiting

  A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

  NCT06056297· Phase 3· X4 Pharmaceuticals· Source

• Active, not recruiting

  A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

  NCT04628494· Phase 3· Genmab· Source

Closed trials

• Completed

  Diabetic Foot Self Care

  NCT07572188· Namik Kemal University· Source

• Terminated

  Futibatinib in Patients With Specific FGFR Aberrations

  NCT04189445· Phase 2· Taiho Oncology, Inc.· Source

• Completed

  Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

  NCT03777657· Phase 3· BeiGene· Source

• Completed

  A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

  NCT03734016· Phase 3· BeiGene· Source

• Completed

  DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

  NCT03523585· Phase 3· Daiichi Sankyo· Source

• Completed

  Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)

  NCT03358875· Phase 3· BeiGene· Source

• Completed

  Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)

  NCT03268954· Phase 3· Takeda· Source

• Completed

  Avelumab in First-line NSCLC (JAVELIN Lung 100)

  NCT02576574· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Hepatitis B9 works · 0 trials